The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae to a new 8-methoxyquinolone, BAY 12-8039, and to ofloxacin, doxycycline, and erythromycin were determined. The activity of BAY 12-8039 was similar to that of ofloxacin, with a MIC at which 90% of the isolates had no inclusions and a minimal chlamydicidal concentration at which 90% of the isolates had no inclusions after passage of 1.0 g/ml, but this activity was less than those of doxycycline and erythromycin.
were frozen at Ϫ70°C, thawed, passaged onto new cells, incubated for 72 h, and then fixed and stained as described above. The MCC was the lowest antibiotic concentration which resulted in no inclusions after passage. All tests were run in triplicate.
The MICs and MCCs of BAY 12-8039 for C. pneumoniae are given in Table 1 . As concentrations of the antibiotics increased, there was a clear point at which the morphology of the inclusions changed, becoming irregular and progressively smaller or frequently abruptly becoming fine dust-like particles. The extent of this phenomenon varied from antibiotic to antibiotic. It was most prominent with ofloxacin. These abnormal forms were not viable when they were passaged onto antibiotic-free cells. The activity of BAY 12-8039 was similar to that of ofloxacin, with a MIC at which 90% of the isolates had no inclusions and an MCC at which 90% of the isolates had no inclusions after passage of 1.0 g/ml. Both quinolones were less active than doxycycline and erythromycin.
The MICs of BAY 12-8039 were very consistent from strain to strain, especially in view of the wide geographic distribution of the isolates tested. Data on the activity of BAY 12-8039 against Chlamydia species are limited. Woodcock et al. (17) tested BAY 12-8039 against three strains of Chlamydia trachomatis and one strain of C. pneumoniae, TW 183. The MICs for C. trachomatis were 0.06 to 0.12 g/ml, and that for C. pneumoniae TW 183 was also 0.06 g/ml, which indicates 10-fold more activity than our results. This discrepancy may be due in part to differences in methods. Woodcock et al. used McCoy cells, which are significantly less susceptible to infection with C. pneumoniae than HEp-2 cells (13). However, they reported that the MICs of another quinolone, ciprofloxacin, for chlamydiae were 1 to 2 g/ml, which are similar to results we have obtained using HeLa cells (3). Felmingham et al. also assessed the activities of BAY 12-8039 against C. trachomatis and C. pneumoniae, although the number and identities of the strains tested were not specified (4). Using iododeoxyuridine-treated McCoy cells, they reported the MICs for both species to be 0.012 g/ml.
Although there are no data on the use of BAY 12-8039 to treat chlamydial infections in humans, preliminary data from a mouse model of C. pneumoniae pneumonia found that the drug was effective in eliminating the organism from the lungs of infected animals (16) . The lung/plasma ratios of the concentrations of BAY 12-8039 ranged from 3.75 to 6.8. After a single 400-mg oral dose in human male volunteers, the maximum concentration of the drug in serum was 3.10 Ϯ 1.12 mg/liter, which is at least three times the MIC for C. pneumoniae (9) . Assuming that BAY 12-8039 is also concentrated in lung tissue in humans, it should be very effective for the treatment of respiratory infections.
BAY 12-8039 has been shown to have excellent activity against gram-positive bacteria such as S. pneumoniae, including strains intermediately and highly resistant to penicillin, and its activity has been shown to exceed those of trovafloxacin, sparfloxacin, ofloxacin, and levofloxacin (2) . It also has good activity against Moraxella catarrhalis, Haemophilus influenzae, and M. pneumoniae (2, 4, 12) . This spectrum of activity suggests that BAY 12-8039 has a role in the treatment of communityacquired pneumonia. However, there are no published reports of studies that have used culture to assess the efficacy of any quinolone for the treatment of C. pneumoniae infection. Lipsky et al. (10) described four patients with bronchitis who had been treated with a 10-day course of ofloxacin and who were retrospectively identified as having had serologic evidence of acute C. pneumoniae infection. All reportedly demonstrated marked clinical improvement. However, as no cultures were done, microbiological efficacy could not be assessed. Plouffe et al. (11) , as part of the Community Acquired Pneumonia Study, retrospectively examined treatment with ofloxacin versus standard therapy (usually a beta-lactam with or without a macrolide) of patients with community-acquired pneumonia requiring hospitalization. Treatment with ofloxacin appeared to be equivalent to standard therapy (11) . However, as the diagnosis of C. pneumoniae was made serologically, only clinical outcome was assessed. File et al. recently reported the results of a large, multicenter pneumonia treatment study comparing treatment with intravenous and/or oral levofloxacin to that with ceftriaxone and/or cefuroxime axetil (5) . As in previous studies (10, 11) , the diagnosis of C. pneumoniae infection was based on serology alone. They found no difference in the clinical responses of those patients who were treated with levofloxacin compared to those who were treated with a cephalosporin. We have treated three patients with culture-documented C. pneumoniae infection (bronchitis and pneumonia) with grepafloxacin, which is slightly more active than ofloxacin in vitro (14) . One patient responded to a 10-day course of grepafloxacin with clinical improvement and eradication of C. pneumoniae from the nasopharynx, but the two other patients remained culture positive and symptomatic despite 2 weeks of treatment with the drug. Prospective studies of BAY 12-8039 for the treatment of community-acquired pneumonia which use culture of C. pneumoniae will determine the role of this drug in the treatment of these infections. 
